Drug Trial Radar · NCT06646289
A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
24
Actual
Start
Oct 10, 2024
Primary completion
Oct 24, 2030
Study completion Oct 24, 2030
Sponsor
- Lead sponsor
- MeiraGTx Ocular UK LtdIndustry
- Sponsor type
- Industry
- First posted
- Oct 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and tolerability of subretinal delivery of Adeno-associated Virus Vector (AAV5 hRKp.RPGR) gene therapy in adults and children with X-linked retinitis pigmentosa.
Conditions
- X-Linked Retinitis Pigmentosa
Interventions
AAV5-hRKp.RPGRBiological
AAV5-hRKp.RPGR will be administered sub-retinally.
No intervention (Follow-Up assessment)Other
Participants will not receive any intervention and will undergo follow-up assessment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AE)Time frame: From baseline up to 5.5 years
- Change from Baseline in Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) Chart Letter ScoresTime frame: Baseline, Months 12, 24, 36, 48 and 60
- Change from Baseline in Low Luminance Visual Acuity (LLVA) by ETDRS Chart Letter ScoreTime frame: Baseline, Months 12, 24, 36, 48 and 60
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Massachusetts Eye and Ear Infirmary
Boston, Massachusetts
University of Michigan Kellogg Eye Center
Ann Arbor, Michigan
Moorfields Eye Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.